Dihydrotestosterone Synthesis Bypasses Testosterone to Drive Castration-Resistant Prostate Cancer Researchers show that the dominant route of dihydrotestosterone (DHT) synthesis in castration-resistant prostate cancer bypasses testosterone, and instead requires 5α-reduction of androstenedione by steroid-5α-reductase isoenzyme-1 to 5α-androstanedione, which is then converted to DHT. [Proc Natl Acad Sci USA]
SCIENCE NEWS
UT Southwestern Scientists Discover New Pathway to Potential Therapies for Advanced Prostate Cancer Researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than was thought previously. [Press release from the University of Texas (UT) Southwestern Medical Center discussing online prepublication in Proceedings of the National Academy of Sciences USA]
Androgen Deprivation Therapy Affects BCL-2 Expression in Human Prostate Cancer Researchers studied BCL-2 expression in vivo in prostate cancer tissues obtained from patients who underwent radical prostatectomy after neoadjuvant androgen deprivation therapy, by Northern and Western blot analysis, and immunohistochemistry. [Int J Oncol] CLINICAL RESEARCH
Adamis Reports APC-300 Kills Human Prostate Cancer Cells Adamis Pharmaceuticals Corporation announced that in addition to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the growth of prostate cancer cells. [Business Wire]
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union Amgen announced that the European Commission has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. [Amgen Press Release]